QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NYSE:CHE

Chemed Stock Forecast, Price & News

$518.98
-21.20 (-3.92 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$518.77
Now: $518.98
$536.70
50-Day Range
$482.45
MA: $529.32
$556.02
52-Week Range
$330.01
Now: $518.98
$560.00
Volume136,252 shs
Average Volume103,638 shs
Market Capitalization$8.28 billion
P/E Ratio31.47
Dividend Yield0.25%
Beta0.55
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Chemed logo

MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

56th out of 1,926 stocks

Home Health Care Services Industry

1st out of 9 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
CUSIP16359R10
Phone513-762-6690
Employees16,641
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.94 billion
Cash Flow$16.90 per share
Book Value$45.39 per share

Profitability

Net Income$219.92 million

Miscellaneous

Market Cap$8.28 billion
Next Earnings Date2/16/2021 (Estimated)
OptionableOptionable
$518.98
-21.20 (-3.92 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHE News and Ratings via Email

Sign-up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chemed (NYSE:CHE) Frequently Asked Questions

How has Chemed's stock price been impacted by Coronavirus (COVID-19)?

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 25.3% and is now trading at $518.98.
View which stocks have been most impacted by COVID-19
.

Is Chemed a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Chemed?

Wall Street analysts have given Chemed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin J. McNamara's approval rating as Chemed's CEO?

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Chemed's next earnings date?

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Chemed
.

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) released its earnings results on Thursday, October, 29th. The company reported $4.86 EPS for the quarter, beating analysts' consensus estimates of $3.97 by $0.89. The firm earned $528.30 million during the quarter, compared to analysts' expectations of $514.22 million. Chemed had a net margin of 13.11% and a trailing twelve-month return on equity of 38.13%. Chemed's revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.46 EPS.
View Chemed's earnings history
.

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed declared a quarterly dividend on Friday, November 6th. Shareholders of record on Monday, November 16th will be given a dividend of $0.34 per share on Monday, December 7th. This represents a $1.36 annualized dividend and a yield of 0.26%. The ex-dividend date is Friday, November 13th.
View Chemed's dividend history
.

Is Chemed a good dividend stock?

Chemed pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.25%. Chemed has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 9.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.51% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

What guidance has Chemed issued on next quarter's earnings?

Chemed issued an update on its FY20 earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of $18.00-18.15 for the period, compared to the Thomson Reuters consensus estimate of $16.35.

What price target have analysts set for CHE?

2 Wall Street analysts have issued 1 year price objectives for Chemed's shares. Their forecasts range from $535.00 to $535.00. On average, they anticipate Chemed's share price to reach $535.00 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for Chemed
or view Wall Street analyst' top-rated stocks.

Are investors shorting Chemed?

Chemed saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 181,100 shares, a drop of 28.2% from the December 15th total of 252,200 shares. Based on an average daily trading volume, of 76,500 shares, the short-interest ratio is presently 2.4 days. Currently, 1.2% of the company's stock are short sold.
View Chemed's Short Interest
.

Who are some of Chemed's key competitors?

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Who are Chemed's key executives?

Chemed's management team includes the following people:
  • Mr. Kevin J. McNamara, CEO, Pres & Director (Age 66, Pay $4.86M)
  • Mr. David P. Williams, Exec. VP & CFO (Age 59, Pay $2.31M)
  • Mr. Spencer S. Lee, Exec. VP (Age 64, Pay $1.44M)
  • Mr. Nicholas Michael Westfall, Exec. VP (Age 41, Pay $1.79M)
  • Mr. Michael D. Witzeman CPA, MBA, VP & Controller (Age 49)
  • Ms. Lisa A. Reinhard, VP, Chief Admin. Officer & Assistant Sec.
  • Sherri Warner, Director of Investor Relations
  • Mr. Brian C. Judkins, VP, Sec. & Chief Legal Officer (Age 40)
  • Mr. Thomas C. Hutton, VP & Director (Age 69)

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Who are Chemed's major shareholders?

Chemed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.32%), Copeland Capital Management LLC (0.58%), Trinity Street Asset Management LLP (0.44%), Boston Trust Walden Corp (0.25%), New York State Teachers Retirement System (0.15%) and Janney Montgomery Scott LLC (0.08%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed
.

Which institutional investors are selling Chemed stock?

CHE stock was sold by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Pacer Advisors Inc., Clark Capital Management Group Inc., Sawgrass Asset Management LLC, We Are One Seven LLC, Miracle Mile Advisors LLC, and Strs Ohio. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed
or view top insider-selling stocks.

Which institutional investors are buying Chemed stock?

CHE stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Trinity Street Asset Management LLP, Copeland Capital Management LLC, Janney Montgomery Scott LLC, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Boston Trust Walden Corp, and Diversified Trust Co.
View insider buying and selling activity for Chemed
or or view top insider-buying stocks.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $518.98.

How big of a company is Chemed?

Chemed has a market capitalization of $8.28 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

What is Chemed's official website?

The official website for Chemed is www.chemed.com.

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.